Design of Selective sPLA2-X Inhibitor (-)-2-{2-[Carbamoyl-6-(trifluoromethoxy)-1H-indol-1-yl]pyridine-2-yl}propanoic Acid

被引：5

作者：

Giordanetto, Fabrizio ^{[1
,8
]}

Knerr, Laurent ^{[1
]}

Nordberg, Peter ^{[1
]}

Pettersen, Daniel ^{[1
]}

Selmi, Nidhal ^{[1
]}

Beisel, Hans-Georg ^{[1
,9
]}

de la Motte, Hannah ^{[1
,10
]}

Mansson, Asa ^{[1
,11
]}

Dahlstrom, Mikael ^{[1
]}

Broddefalk, Johan ^{[1
]}

Saarinen, Gabrielle ^{[1
,12
]}

Klingegard, Fredrik ^{[1
,13
]}

Hurt-Camejo, Eva ^{[2
]}

Rosengren, Birgitta ^{[3
]}

Wikstrom, Johannes ^{[3
]}

Wagberg, Maria ^{[3
]}

Brengdahl, Johan ^{[5
]}

Rohman, Mattias ^{[5
]}

Sandmark, Jenny ^{[7
]}

Akerud, Tomas ^{[7
]}

Roth, Robert G. ^{[7
]}

Jansen, Frank ^{[6
]}

Ahlqvist, Marie ^{[4
]}

机构：

[1] AstraZeneca, IMED Biotech Unit, Med Chem, SE-43189 Gothenburg, Sweden

[2] AstraZeneca, IMED Biotech Unit, Translat Sci, SE-43189 Gothenburg, Sweden

[3] AstraZeneca, IMED Biotech Unit, Biosci, SE-43189 Gothenburg, Sweden

[4] AstraZeneca, IMED Biotech Unit, Drug Metab & Pharmacokinet, Cardiovasc & Metab Dis, SE-43189 Gothenburg, Sweden

[5] AstraZeneca, IMED Biotech Unit, Reagents & Assay Dev, SE-43189 Gothenburg, Sweden

[6] AstraZeneca, IMED Biotech Unit, Mechanist Biol & Profiling, SE-43189 Gothenburg, Sweden

[7] AstraZeneca, IMED Biotech Unit, Struct & Biophys, Discovery Sci, SE-43189 Gothenburg, Sweden

[8] DE Shaw Res, 120 W 45th St, New York, NY 10036 USA

[9] Medivir AB, SE-14122 Huddinge, Sweden

[10] Sweden Div Bioecon, RISE Res Inst, SE-41756 Gothenburg, Sweden

[11] Alfa Laval Lund AB, SE-22655 Lund, Sweden

[12] SCA Hyg Prod AB, SE-85188 Stockholm, Sweden

[13] SciLifeLab, Drug Discovery & Dev Platform, SE-17121 Solna, Sweden

来源：

ACS MEDICINAL CHEMISTRY LETTERS | 2018年 / 9卷 / 07期

关键词：

Secreted phospholipase A2 type X; sPLA2-X; inhibitor; atherosclerosis; coronary artery disease; carotid ligation; GROUP-X; SECRETORY PHOSPHOLIPASE-A(2); ATHEROSCLEROSIS; ARTERY; A(2);

D O I：

10.1021/acsmedchemlett.7b00507

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A lead generation campaign identified indolebased sPLA(2)-X inhibitors with a promising selectivity profile against other sPLA(2) isoforms. Further optimization of sPLA(2) selectivity and metabolic stability resulted in the design of (-)-17, a novel, potent, and selective sPLA(2)-X inhibitor with an exquisite pharmacokinetic profile characterized by high absorption and low clearance, and low toxicological risk. Compound (-)-17 was tested in an ApoE(-/-) murine model of atherosclerosis to evaluate the effect of reversible, pharmacological sPLA(2)-X inhibition on atherosclerosis development. Despite being well tolerated and achieving adequate systemic exposure of mechanistic relevance, (-)-17 did not significantly affect circulating lipid and lipoprotein biomarkers and had no effect on coronary function or histological markers of atherosclerosis.

引用

页码：600 / 605

页数：11

共 50 条

[41] 2-(1H-Benzoimidazol-2-yl)-6-ethoxyphenol
Yeap, Chin Sing
Kargar, Hadi
Kia, Reza
Jamshidvand, Arezoo
Fun, Hoong-Kun
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2009, 65 : O745 - U1931
[42] 2-(1H-Tetrazol-1-yl)benzoic acid
Lyakhov, AS
Gaponik, PN
Voitekhovich, SV
Ivashkevich, LS
Kulak, AA
Ivashkevich, OA
ACTA CRYSTALLOGRAPHICA SECTION C-STRUCTURAL CHEMISTRY, 2001, 57 (12): : 1436 - 1437
[43] Calorimetric and computational study of (1H-Indol-n-yl)methanol and 2-(1H-Indol-n-yl)ethanol (n=2, 3)
Carvalho, Tania M. T.
Amaral, Luisa M. P. F.
Morais, Victor M. F.
Ribeiro da Silva, Maria D. M. C.
THERMOCHIMICA ACTA, 2019, 673 : 169 - 176
[44] 2-[(E)-2-(1H-Indol-3-yl)ethenyl]-1-methylpyridinium 4-chlorobenzenesulfonate
Kobkeatthawin, Thawanrat
Chantrapromma, Suchada
Fun, Hoong-Kun
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2009, 65 : O2045 - U4584
[45] Discovery of N-(1-Acryloylazetidin-3-yl)-2-(1H-indol-1-yl)acetamides as Covalent Inhibitors of KRASG12C
Shin, Youngsook
Jeong, Joon Won
Wurz, Ryan P.
Achanta, Pragathi
Arvedson, Tara
Bartberger, Michael D.
Campuzano, Iain D. G.
Fucini, Ray
Hansen, Stig K.
Ingersoll, John
Iwig, Jeffrey S.
Lipford, J. Russell
Ma, Vu
Kopecky, David J.
McCarter, John
San Miguel, Tisha
Mohr, Christopher
Sabet, Sudi
Saiki, Anne Y.
Sawayama, Andrew
Sethofer, Steven
Tegley, Christopher M.
Volak, Laurie P.
Yang, Kevin
Lanman, Brian A.
Erlanson, Daniel A.
Cee, Victor J.
ACS MEDICINAL CHEMISTRY LETTERS, 2019, 10 (09): : 1302 - 1308
[46] 2-[(E)-2-(1H-Indol-3-yl)ethenyl]-1-methylpyridinium 4-bromobenzenesulfonate
Chantrapromma, Suchada
Kobkeatthawin, Thawanrat
Fun, Hoong-Kun
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2009, 65 : O950 - U1396
[47] Diethyl 2-[(2-benzyl-1-phenylsulfonyl-1H-indol-3-yl)methylene]malonate
Kavitha, T.
Thenmozhi, M.
Dhayalan, V.
Mohanakrishnan, A. K.
Ponnuswamy, M. N.
ACTA CRYSTALLOGRAPHICA SECTION E-STRUCTURE REPORTS ONLINE, 2009, 65 : O12 - U1368
[48] Crystal structure of 2-(2-bromophenyl)-4-(1H-indol-3-yl)-6-(thiophen-2-yl)pyridine-3-carbonitrile
Vishnupriya, R.
Suresh, J.
Bharkavi, Shanmugavel
Perumal, Subbu
Lakshman, P. L. Nilantha
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2014, 70 : O968 - +
[49] Methyl 2-({6-[(1-methoxy-2-methyl-1-oxopropan-2-yl)carbamoyl]pyridin-2-yl}formamido)-2-methylpropanoate
Al-Omar, Mohamed A.
Amr, Abdel-Galil E.
Ghabbour, Hazem A.
Quah, Ching Kheng
Fun, Hoong-Kun
ACTA CRYSTALLOGRAPHICA SECTION E-CRYSTALLOGRAPHIC COMMUNICATIONS, 2012, 68 : O1377 - +
[50] 2-(1,3-Oxazolin-2-yl)pyridine and 2,6-bis (1,3-oxazolin-2-yl) pyridine
Ochedzan-Siodlak, Wioletta
Bihun-Kisiel, Anna
Siodlak, Dawid
Poliwoda, Anna
Dziuk, Blazej
DATA IN BRIEF, 2018, 21 : 449 - 465

← 1 2 3 4 5 →